Constitutive activation of c-Abl/protein kinase C-δ/Fli1 pathway in dermal fibroblasts derived from patients with localized scleroderma

British Journal of Dermatology

Volumn 167, Issue 5, 2012, Pages 1098-1105

  Noda, S ^a   Asano, Y ^a   Akamata, K ^a   Aozasa, N ^a   Taniguchi, T ^a   Takahashi, T ^a   Ichimura, Y ^a   Toyama, T ^a   Sumida, H ^a   Yanaba, K ^a   Tada, Y ^a   Sugaya, M ^a   Kadono, T ^a   Sato, S ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

6,7 DIMETHOXY 2 PHENYLQUINOXALINE; ABELSON KINASE; COLLAGEN TYPE 1; IMATINIB; MESSENGER RNA; PROTEIN FLI1; PROTEIN KINASE C DELTA; THREONINE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; CELL NUCLEUS; CHILD; CHROMATIN IMMUNOPRECIPITATION; COLLAGEN SYNTHESIS; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME LOCALIZATION; FEMALE; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LOCALIZED SCLERODERMA; MALE; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN PHOSPHORYLATION; SCLERODERMA; SKIN FIBROBLAST;

ADOLESCENT; ADULT; CASE-CONTROL STUDIES; CELLS, CULTURED; CHILD; CHILD, PRESCHOOL; FEMALE; FIBROBLASTS; HUMANS; MALE; MIDDLE AGED; PHOSPHORYLATION; PIPERAZINES; PROTEIN KINASE C-DELTA; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEIN C-FLI-1; PROTO-ONCOGENE PROTEINS C-ABL; PYRIMIDINES; SCLERODERMA, LOCALIZED; TRANSFORMING GROWTH FACTOR BETA;

EID: 84868205560     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2012.11055.x     Document Type: Article

References (41)

1. Asano Y, Ihn H, Jinnin M, et al. Involvement of alphaVbeta5 integrin in the establishment of autocrine TGF-beta signaling in dermal fibroblasts derived from localized scleroderma. J Invest Dermatol 2006; 126: 1761-9.
2. LeRoy EC,. Increased collagen synthesis by scleroderma skin fibroblasts in vitro: a possible defect in the regulation or activation of the scleroderma fibroblast. J Clin Invest 1974; 54: 880-9.
3. Fett N, Werth VP,. Update on morphea: part II. Outcome measures and treatment. J Am Acad Dermatol 2011; 64: 231-42.
4. Kubo M, Ihn H, Yamane K, et al. Up-regulated expression of transforming growth factor beta receptors in dermal fibroblasts in skin sections from patients with localized scleroderma. Arthritis Rheum 2001; 44: 731-4.
5. Trojanowska M,. Noncanonical transforming growth factor beta signaling in scleroderma fibrosis. Curr Opin Rheumatol 2009; 21: 623-9.
6. Bujor AM, Asano Y, Haines P, et al. The c-Abl tyrosine kinase controls protein kinase Cδ-induced Fli-1 phosphorylation in human dermal fibroblasts. Arthritis Rheum 2011; 63: 1729-37.
7. Hollenhorst PC, Jones DA, Graves BJ,. Expression profiles frame the promoter specificity dilemma of the ETS family of transcription factors. Nucleic Acids Res 2004; 32: 5693-702.
8. Czuwara-Ladykowska J, Shirasaki F, Jackers P, et al. Fli-1 inhibits collagen type I production in dermal fibroblasts via an Sp1-dependent pathway. J Biol Chem 2001; 276: 20839-48.
9. Asano Y, Czuwara J, Trojanowska M,. Transforming growth factor-beta regulates DNA binding activity of transcription factor Fli1 by p300/CREB-binding protein-associated factor-dependent acetylation. J Biol Chem 2007; 282: 34672-83.
10. Nakerakanti SS, Kapanadze B, Yamasaki M, et al. Fli1 and Ets1 have distinct roles in connective tissue growth factor/CCN2 gene regulation and induction of the profibrotic gene program. J Biol Chem 2006; 281: 25259-69.
11. Asano Y, Trojanowska M,. Phosphorylation of Fli1 at threonine 312 by protein kinase C delta promotes its interaction with p300/CREB-binding protein-associated factor and subsequent acetylation in response to transforming growth factor beta. Mol Cell Biol 2009; 29: 1882-94.
12. Asano Y, Markiewicz M, Kubo M, et al. Transcription factor Fli1 regulates collagen fibrillogenesis in mouse skin. Mol Cell Biol 2009; 29: 425-34.
13. Distler JH, Distler O,. Tyrosine kinase inhibitors for the treatment of fibrotic diseases such as systemic sclerosis: towards molecular targeted therapies. Ann Rheum Dis 2010; 69 (Suppl. 1): i48-51.
14. Spiera RF, Gordon JK, Mersten JN, et al. Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial. Ann Rheum Dis 2011; 70: 1003-9.
15. Pope J, McBain D, Petrlich L, et al. Imatinib in active diffuse cutaneous systemic sclerosis: results of a six-month, randomized, double-blind, placebo-controlled, proof-of-concept pilot study at a single center. Arthritis Rheum 2011; 63: 3547-51.
16. Khanna D, Saggar R, Mayes MD, et al. A one-year, phase I/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease. Arthritis Rheum 2011; 63: 3540-6.
17. Tamaki Z, Asano Y, Hatano M, et al. Efficacy of low-dose imatinib mesylate for cutaneous involvement in systemic sclerosis: a preliminary report of three cases. Mod Rheumatol 2012; 22: 94-9.
18. Sfikakis PP, Gorgoulis VG, Katsiari CG, et al. Imatinib for the treatment of refractory, diffuse systemic sclerosis. Rheumatology (Oxford) 2008; 47: 735-7.
19. Moinzadeh P, Krieg T, Hunzelmann N,. Imatinib treatment of generalized localized scleroderma (morphea). J Am Acad Dermatol 2010; 63: e102-4.
20. Asano Y, Ihn H, Yamane K, et al. Increased expression levels of integrin alphaVbeta5 on scleroderma fibroblasts. Am J Pathol 2004; 164: 1275-92.
21. Ihn H, Tamaki K,. Competition analysis of the human alpha2(I) collagen promoter using synthetic oligonucleotides. J Invest Dermatol 2000; 114: 1011-16.
22. Asano Y, Ihn H, Yamane K, et al. Impaired Smad7-Smurf-mediated negative regulation of TGF-beta signaling in scleroderma fibroblasts. J Clin Invest 2004; 113: 253-64.
23. Esposito F, Chirico G, Montesano Gesualdi N, et al. Protein kinase B activation by reactive oxygen species is independent of tyrosine kinase receptor phosphorylation and requires SRC activity. J Biol Chem 2003; 278: 20828-34.
24. Kovalenko M, Gazit A, Böhmer A, et al. Selective platelet-derived growth factor receptor kinase blockers reverse sis-transformation. Cancer Res 1994; 54: 6106-14.
25. Lipson KE, Pang L, Huber LJ, et al. Inhibition of platelet-derived growth factor and epidermal growth factor receptor signaling events after treatment of cells with specific synthetic inhibitors of tyrosine kinase phosphorylation. J Pharmacol Exp Ther 1998; 285: 844-52.
26. Petti LM, Ray FA,. Transformation of mortal human fibroblasts and activation of a growth inhibitory pathway by the bovine papillomavirus E5 oncoprotein. Cell Growth Differ 2000; 11: 395-408.
27. Giacco F, Perruolo G, D'Agostino E, et al. Thrombin-activated platelets induce proliferation of human skin fibroblasts by stimulating autocrine production of insulin-like growth factor-1. FASEB J 2006; 20: 2402-4.
28. Pannu J, Nakerakanti S, Smith E, et al. Transforming growth factor-beta receptor type I-dependent fibrogenic gene program is mediated via activation of Smad1 and ERK1/2 pathways. J Biol Chem 2007; 282: 10405-13.
29. Einav U, Tabach Y, Getz G, et al. Gene expression analysis reveals a strong signature of an interferon-induced pathway in childhood lymphoblastic leukemia as well as in breast and ovarian cancer. Oncogene 2005; 24: 6367-75.
30. Akada H, Yan D, Zou H, et al. Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease. Blood 2010; 115: 3589-97.
31. Jinnin M, Ihn H, Yamane K, et al. Alpha2(I) collagen gene regulation by protein kinase C signaling in human dermal fibroblasts. Nucleic Acids Res 2005; 33: 1337-51.
32. Jimenez SA, Gaidarova S, Saitta B, et al. Role of protein kinase C-delta in the regulation of collagen gene expression in scleroderma fibroblasts. J Clin Invest 2001; 108: 1395-403.
33. Kubo M, Czuwara-Ladykowska J, Moussa O, et al. Persistent down-regulation of Fli1, a suppressor of collagen transcription, in fibrotic scleroderma skin. Am J Pathol 2003; 163: 571-81.
34. Wipff PJ, Rifkin DB, Meister JJ, et al. Myofibroblast contraction activates latent TGF-beta1 from the extracellular matrix. J Cell Biol 2007; 179: 1311-23.
35. Asano Y, Ihn H, Yamane K, et al. Involvement of alphaVbeta5 integrin-mediated activation of latent transforming growth factor beta1 in autocrine transforming growth factor beta signaling in systemic sclerosis fibroblasts. Arthritis Rheum 2005; 52: 2897-905.
36. Asano Y, Ihn H, Yamane K, et al. Increased expression of integrin alphaVbeta5 induces the myofibroblastic differentiation of dermal fibroblasts. Am J Pathol 2006; 168: 499-510.
37. Asano Y, Bujor AM, Trojanowska M,. The impact of Fli1 deficiency on the pathogenesis of systemic sclerosis. J Dermatol Sci 2010; 59: 153-62.
38. Liu F, Walmsley M, Rodaway A, et al. Fli1 acts at the top of the transcriptional network driving blood and endothelial development. Curr Biol 2008; 18: 1234-40.
39. Wang Y, Fan PS, Kahaleh B,. Association between enhanced type I collagen expression and epigenetic repression of the FLI1 gene in scleroderma fibroblasts. Arthritis Rheum 2006; 54: 2271-9.
40. Asano Y, Stawski L, Hant F, et al. Endothelial Fli1 deficiency impairs vascular homeostasis: a role in scleroderma vasculopathy. Am J Pathol 2010; 176: 1983-98.
41. Varga J, Abraham D,. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 2007; 117: 557-67.